Roche Holding AG's Fiscal Year is From January To December - All Figures are in CHF, Billions.
The item "Interest-Expense" stands at 2.28 Billion Swiss Francs for the trailing twelve months (TTM) period ending 06/30/2025.
Roche Holding AG's second quarter result of 0.608 Billion CHF for the item "Interest Expense" represents an increase of 20.00 percent compared to it's first quarter result.
Also, Roche Holding AG's second quarter result of 0.608 Billion CHF for the item "Interest Expense" represents a decrease of -2.72 percent compared to it's second quarter result of last year.
Looking again at the trailing twelve months series (TTM), Roche Holding AG's second quarter result of 2.28 Billion CHF for the item "Interest Expense" represents a decrease of -0.74 percent compared to it's first quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 40.16 percent compared to the value the year prior.
The 1 year change in percent is 40.16.
The 3 year change in percent is 283.67.
The 5 year change in percent is 204.87.
The 10 year change in percent is 101.74.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Interest Expense | 905,699,262,464.00 |
![]() | Johnson & Johnson - Interest Expense | 486,508,953,600.00 |
![]() | AbbVie Inc - Interest Expense | 399,570,305,024.00 |
![]() | AstraZeneca PLC - Interest Expense | 280,205,508,085.11 |
![]() | Novartis AG - Interest Expense | 255,096,620,580.91 |